Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2022-10-21 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Dividend
Regulatory Filings
2022-10-21 English
Outcome of Board Meeting
Regulatory Filings
2022-10-21 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 90% confidence The document is an announcement for a conference call regarding Q2 & 1H FY23 results of Laurus Labs Ltd. It provides details about the timing, dial-in numbers, and registration link for the call. It mentions a management discussion and Q&A session but does not contain any actual financial data or detailed financial statements. The document length is 3464 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement or invitation rather than the transcript itself. However, since it is only announcing the call and not providing the transcript, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the call. The document does not fit the criteria for other categories such as Earnings Release (ER) or Interim Report (IR) because it lacks financial data. Hence, the most appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-10-13 English
Board Meeting — Dividend/Financial results
Board/Management Information Classification · 95% confidence The document is a notification about an upcoming Board Meeting scheduled for October 21, 2022, where the Board will consider and approve the unaudited financial results for the quarter and half year ended September 30, 2022, and discuss an interim dividend proposal. It is an intimation sent to stock exchanges as per SEBI regulations. The document does not contain actual financial results or detailed reports but is an announcement of a board meeting and its agenda. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1818 characters), and it is clearly an announcement, not a report or transcript.
2022-10-13 English
General updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialization of securities during the quarter ended September 30, 2022. It is addressed to stock exchanges and regulatory bodies, and it is a compliance certificate rather than a financial report or announcement of financial results. The document length is short (1886 characters) and it serves as a regulatory compliance filing. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate.
2022-10-10 English
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of un-audited financial results for the quarter and half-year ended September 30, 2022. It does not contain any financial data or results itself, nor does it present a report. It is an announcement related to compliance and trading restrictions before financial results are declared. The document length is short (1509 characters) and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2022-09-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.